PharmaCann gets extension on Ohio cannabis grow facility key to MedMen deal

PharmaCann, which is due to merge with MedMen via a $682 million stock deal, received a state extension until October to complete the development of a cultivation facility in Buckeye Lake, Ohio.

The $20 million cultivation center must be operational before California-based MedMen can complete the acquisition of PharmaCann, according to Columbus Business First. That’s because Ohio requires a licensee have certification to begin operating before it’s allowed to transfer a license to another owner, the publication noted.

The business website added that the acquisition is expected to take up to another 12 months to complete because of the multiple states in which PharmaCann operates.

MedMen trades on the Canadian Securities Exchange as MMEN and on U.S. over-the-counter markets as MMNFF.

Get access to more in-depth market analysis, premium features on cannabis investing trends and monthly executive webcasts with an Investor Intelligence subscription.

2 comments on “PharmaCann gets extension on Ohio cannabis grow facility key to MedMen deal
  1. Catherine Slisz on

    I own both stocks, (MMEN) on the CSE and (MMNFF) on the US OTC Market. I’ve had them for about 9 months. Is what you’re saying, that it’s going to take until at least 12 months before either company starts to show any kind of profit? Wasn’t Pharma Cann the name that CRONOS went under before it changed to CRONOS? Does Pharma Cann have a trading symbol of it’s own either in Canada or the US.? I’d be interested in finding out.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *